ScholarLens Back to search
2006•Molecular TherapyOpen access

32. Improvement of Muscle Mass Using shRNA Targeting Myostatin or Activin Receptor IIb

Julie Dumonceaux, Solenne Marie, Luis Garcı́a

Open full text 0 citations

Abstract

Duchenne Muscular Dystrophy (DMD) is the most severe degenerative disorder of skeletal and cardiac muscle. DMD patients show a progressive muscle weakness which begins in early childhood. Our goal is to stop this continuous muscle wasting.

Open-access reader

About this research paper

What this paper is about

Duchenne Muscular Dystrophy (DMD) is the most severe degenerative disorder of skeletal and cardiac muscle. DMD patients show a progressive muscle weakness which begins in early childhood. Our goal is to stop this continuous muscle wasting.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Duchenne Muscular Dystrophy (DMD) is the most severe degenerative disorder of skeletal and cardiac muscle. DMD patients show a progressive muscle weakness which begins in early childhood. Our goal is to stop this continuous muscle wasting.

Key concepts: Myostatin, Activin receptor, ACVR2B, Follistatin, Small hairpin RNA, Activin type 2 receptors, Receptor, Cell biology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
32. Improvement of Muscle Mass Using shRNA Targeting Myostatin or Activin Receptor IIb — Research Paper | ScholarLens